NY-AQARA
28.7.2021 10:02:05 CEST | Business Wire | Press release
Aqara, a provider for smart home products, announced the launch of its first Amazon store in Europe, the Aqara Amazon UK store . Starting from July 28, 2021, a comprehensive suite of Aqara products will be made available on Amazon UK to residents not only in the UK, but also in dozens of European countries that are covered in the Amazon network.
Aqara has been selling smart home products in Europe since 2020 via dozens of authorized distributors , and has become one of the most popular brands among the European smart home community for the high product quality, the accessible prices and the seamless integration with major ecosystems including Apple HomeKit, Amazon Alexa, Google Assistant, and more.
The launch of Aqara’s first Amazon Europe store marks another milestone for the fast-growing brand, offering millions of European consumers an easy and convenient access to the Aqara product lineup. Following its UK Amazon store, Aqara is expected to add two more brand stores on Amazon France and Amazon Germany in the following months.
The product lineup on the Aqara Amazon UK store include:
Aqara Hub M2 (£54.99*) - Aqara’s most advanced and future-proof smart home hub that connects all Aqara devices and allows seamless integration across Aqara sensors and home automation devices;
Aqara Camera Hub G2H (£64.99) - An indoor HomeKit Secure Video camera for home security, with the Zigbee hub function to enhance home security and smart home automations;
Aqara Door & Window Sensor (£17.99) - It detects if a window or a door is open in real time, and enables push notifications or/and local alarm activation when the door/ window opens unexpectedly;
Aqara Temperature & Humidity Sensor (£19.99) - It monitors temperature, humidity, and atmospheric pressure in real time, and can connect with other Aqara devices for home automations and scenes;
Aqara Motion Sensor (£21.99) - It detects human movements with passive infrared and can work with other Aqara products to set home automations and scenes, such as turning on/off lights when it detects activity or inactivity;
Aqara Water Leak Sensor (£19.99) - It detects flood, and enables push notifications or/and local alarm activation to protect the property;
Aqara Vibration Sensor (£19.99) - It detects vibration, tilt and drop, alerts users when unexpected movement is detected, and can be used for home automations and scenes;
Aqara Wireless Switch H1 (£26.99) - A remote switch with 7 configurable actions to control smart home devices or home scenes;
Aqara Wireless Mini Switch (£17.99) - A versatile and compact switch with 3 configurable actions to control smart home devices or home scenes;
Aqara Cube (£19.99) - A versatile controlling cube that recognizes 6 gestures (push, shake, rotate, tap twice, flip 90°, and flip 180°) for smart home control;
Aqara TVOC Air Quality Monitor** (£39.99) - It detects the concentration and level of total volatile organic compounds (TVOC) in the air, as well as temperature and humidity, and can be bound with an Aqara hub to enable home automations;
Aqara Smart Wall Switch H1 EU** (£39.99-£42.99) - Aqara’s first wall switch designed for Europe, available in both With Neutral and No Neutral versions;
To celebrate the launch, Aqara now offers a limited-time discount of 10% OFF for all purchases on its Amazon UK store with the promo code: AmazonUKPR. The offering is valid through July 30, 2021.
* All prices include VAT.
** Aqara TVOC Air Quality Monitor and Wall Switch H1 EU will be available on Amazon UK in the following weeks.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210728005229/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom